Mantle Cell Lymphoma: E1411 (Hematology Oncology Associates)

E1411 Intergroup Randomized Phase 2 Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+Bendamustine Followed by Rituximab Consolidation (RB -->R); Arm B = Rituximab+Bendamustine+Bortezomib Followed By Rituximab Consolidation (RBV--> R), Arm C = Rituximab+Bendamustine Followed by Lenalidomide+Rituximab Consolidation (RB --> LR) or Arm D = Rituximab+Bendamustine+Bortezomib Followed by Lenalidomide+Rituximab Consolidation (RBV --> LR)

Objective

The purpose of this study is two fold and has two steps of treatment:

1)  In step 1, to find out what effects, good and bad, the addition of bortezomib (Velcade) to rituximab (Rituxan) plus bendamustine (TREANDA) has on patients with mantle cell lymphoma compared to rituximab plus bendamustine alone.

2)  In step 2, to find out what effects, good and bad, continuing treatment after step 1 with lenalidomide (Revlimid) plus rituximab has on patients with mantle cell lymphoma compared to continuing treatment with rituximab alone.



Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Lymphoma
Sponsor(s)
Eastern Cooperative Oncology Group
Contact
Katy D'Aprile, RN, BSN at 563-355-7733

Location

  • Hematology Oncology Associates of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email